Featured Research

from universities, journals, and other organizations

Lapatinib Reduces Brain Metastases In Mouse Model Of Metastatic Breast Cancer

Date:
August 4, 2008
Source:
Journal of the National Cancer Institute
Summary:
Lapatinib reduces the number of large brain metastases in a mouse model of metastatic breast cancer, relative to untreated mice, researchers report.

Lapatinib reduces the number of large brain metastases in a mouse model of metastatic breast cancer, relative to untreated mice, researchers report in the July 29 online issue of the Journal of the National Cancer Institute.

Related Articles


Symptomatic brain metastases affect between 10 and 20 percent of women with metastatic breast cancer, and the problem is particularly common for women whose tumors overexpress the HER2 protein. However, trastuzumab, an antibody that blocks the HER2 protein activity and is the standard of care for HER2-positive disease, does not cross the blood–brain barrier. Therefore, other therapies are needed to reduce the brain metastases in patients with HER2-positive disease. Lapatinib, a small-molecule inhibitor of both HER2 and the epidermal growth factor receptor (EGFR), is able to cross the blood–brain barrier.

In the current study, Patricia Steeg, Ph.D., of the National Cancer Institute and colleagues injected mice with a breast cancer cell line that preferentially gives rise to metastases in the brain, called MDA-MB-231-BR. The researchers engineered some of the cells to overexpress the HER2 protein. Five days after the mice were injected with the cancer cells, the researchers started treating them with lapatinib or a placebo. After 24 days of therapy, the investigators measured and counted brain metastases.

Among mice injected with the HER2-overexpressing cells, those treated with lapatinib developed fewer than half of the large metastases as those that did not receive the drug. A similar reduction occurred among mice injected with the unmodified cells, although a higher dose of lapatinib was required. Lapatinib did not completely prevent the formation of brain metastases, suggesting that some of the tumor cells are resistant to the drug.

"We propose a scenario in which standard treatments such as neurosurgery and stereotactic radiosurgery are used to treat clinical metastases and currently unavailable molecular therapeutics are then used to hold the remaining micrometastases in check. One possible molecular therapeutic is lapatinib, a dual inhibitor of EGFR and HER2 kinases," the authors write.


Story Source:

The above story is based on materials provided by Journal of the National Cancer Institute. Note: Materials may be edited for content and length.


Cite This Page:

Journal of the National Cancer Institute. "Lapatinib Reduces Brain Metastases In Mouse Model Of Metastatic Breast Cancer." ScienceDaily. ScienceDaily, 4 August 2008. <www.sciencedaily.com/releases/2008/07/080729235406.htm>.
Journal of the National Cancer Institute. (2008, August 4). Lapatinib Reduces Brain Metastases In Mouse Model Of Metastatic Breast Cancer. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2008/07/080729235406.htm
Journal of the National Cancer Institute. "Lapatinib Reduces Brain Metastases In Mouse Model Of Metastatic Breast Cancer." ScienceDaily. www.sciencedaily.com/releases/2008/07/080729235406.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Solitair Device Aims to Takes Guesswork out of Sun Safety

Solitair Device Aims to Takes Guesswork out of Sun Safety

Reuters - Innovations Video Online (Mar. 31, 2015) — The Solitair device aims to take the confusion out of how much sunlight we should expose our skin to. Small enough to be worn as a tie or hair clip, it monitors the user&apos;s sun exposure by taking into account their skin pigment, location and schedule. Matthew Stock reports. Video provided by Reuters
Powered by NewsLook.com
Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins